Can a consumer DNA test interpret APOE reliably?

Consumer DNA tests can technically genotype the common APOE variants (rs429358, rs7412) with high accuracy, as these are well-validated SNPs. However, the interpretation of APOE for Alzheimer's disease risk is complex and not straightforward. While the ε4 allele is the strongest known common genetic risk factor for late-onset Alzheimer's, it is neither necessary nor sufficient for disease development. Many ε4 carriers never develop Alzheimer's, and many people without ε4 do. Therefore, a positive result does not mean a person will get the disease, and a negative result does not rule it out. Furthermore, DTC tests are not diagnostic and should not replace clinical evaluation. The clinical utility of APOE testing is debated; some guidelines recommend against routine testing due to lack of effective prevention strategies and potential psychological harm. Evidence for genotyping reliability is strong (human-strong), but for clinical interpretation it is moderate to mixed. Consumers should seek genetic counseling before and after testing.